A big step for MYC-targeted therapies

Danielle F Atibalentja; Anja Deutzmann; Dean W Felsher

doi:10.1016/j.trecan.2024.03.009

A big step for MYC-targeted therapies

Trends Cancer. 2024 May;10(5):383-385. doi: 10.1016/j.trecan.2024.03.009. Epub 2024 Apr 5.

Authors

Danielle F Atibalentja¹, Anja Deutzmann¹, Dean W Felsher²

Affiliations

¹ Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA.
² Division of Oncology, Department of Medicine, Stanford University, Stanford, CA 94305, USA; Department of Pathology, Stanford University, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA 94305, USA. Electronic address: dfelsher@stanford.edu.

Abstract

The MYC proto-oncogene encodes a master transcriptional regulator that is frequently dysregulated in human cancer. Decades of efforts have failed to identify a MYC-targeted therapeutic, and this is still considered to be a holy grail in drug development. We highlight a recent report by Garralda et al. of a Phase 1 clinical trial of OMO-103 in patients with solid malignancies.

Keywords: MYC; OMO-103; Omomyc; cancer; immunotherapy; oncogene addiction; tumor.

MeSH terms

Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Clinical Trials, Phase I as Topic
Gene Expression Regulation, Neoplastic / drug effects
Humans
Molecular Targeted Therapy* / methods
Neoplasms* / drug therapy
Neoplasms* / genetics
Neoplasms* / therapy
Proto-Oncogene Mas*
Proto-Oncogene Proteins c-myc* / antagonists & inhibitors
Proto-Oncogene Proteins c-myc* / genetics
Proto-Oncogene Proteins c-myc* / metabolism

Abstract

MeSH terms

Grants and funding